Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone
NCT01279187 · University of Michigan · PHASE2 · terminated · last registry update 2018-02-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due to patient complications unrelated to study drugs” | – | Registry record, University of Michigan |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTH1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-12-14Results posted on the registry: Amgen, Placebo to Romosozumab + Alendronate (NCT00896532)
- 2018-11-08Results posted on the registry: Amgen, Romozosumab + Teriparatide (NCT01796301)
- 2018-10-18Phase 3 first posted: Radius Health, Inc., Abaloparatide (NCT03710889)
- 2018-09-26Results posted on the registry: Northwestern University, Alendronate (NCT02195895)
- 2018-09-25Results posted on the registry: Northwestern University, Teriparatide (NCT02025179)
- 2018-07-31Results posted on the registry: Zosano Pharma Corporation, teriparatide + teriparatide (NCT00489918)
- 2018-07-26Results posted on the registry: Columbia University, Teriparatide (PTH 1-34) (NCT00697463)
- 2018-05-08Results posted on the registry: Massachusetts General Hospital, denosumab + teriparatide (NCT00926380)
- 2018-04-30Phase 3 first posted: Radius Health, Inc., Abaloparatide + Placebo (NCT03512262)
- 2018-01-23Results posted on the registry: Eli Lilly and Company, Teriparatide + Risedronate (NCT01709110)
- 2017-12-12Results posted on the registry: Susan L. Greenspan, teriparatide (NCT01705587)
- 2017-11-07Also stopped (terminated): GlaxoSmithKline, Ronacaleret + Teriparatide (NCT00471237)
- 2017-09-05Results posted on the registry: GlaxoSmithKline, Ronacaleret + Teriparatide (NCT00471237)
- 2017-08-04Results posted on the registry: University of Pennsylvania, Teriparatide + Zoledronic Acid (NCT01153425)
- 2017-06-22Results posted on the registry: Thomas J. Schnitzer, Teriparatide (NCT01225055)
- 2017-04-28Phase 3 first posted: King Chulalongkorn Memorial Hospital, Teriparatide + Placebo (NCT03133195)
- 2017-04-11Results posted on the registry: Brigham and Women's Hospital, Teriparatide + calcium citrate (NCT01400516)
- 2017-03-28Results posted on the registry: Massachusetts General Hospital, Placebo + Teriparatide (NCT00759772)
- 2017-03-01Results posted on the registry: Radius Health, Inc., Placebo + BA058 80 mcg (NCT01343004)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision